Newsroom
July 13, 2023
Be sure to catch up on the latest happenings in our summer newsletter.
May 25, 2023
By Shelley Wood MAY 23, 2023
May 3, 2023
| By Ultromics
Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.
April 24, 2023
WILMINGTON, Del.--(BUSINESS WIRE)--Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.1
April 19, 2023
Be sure to catch up on the latest happenings in our spring newsletter.